JCI Insight · 2021 · 33 citations · 65 references
Life SciencesImmunologyNeuroscienceAutoimmunityImmunotherapyNeuroimmunologyAutoimmune Neurological DisordersEffector T Cell FunctionMultiple SclerosisMultiple Sclerosis PharmacotherapyNeuroinflammationRegulatory T CellsCd4 Positive T CellsExperimental Autoimmune EncephalomyelitisMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis TherapyRelapsing-remitting Multiple Sclerosis TreatmentSmall-molecule Prodrug DesignStat3 SignalingTh17 Cell Differentiation
Reestablishing an appropriate balance between T effector cells (Teff) and Tregs is essential for correcting autoimmunity. Multiple sclerosis (MS) is an immune-mediated chronic CNS disease characterized by neuroinflammation, demyelination, and neuronal degeneration, in which the Teff:Treg balance is skewed toward pathogenic Teffs Th1 and Th17 cells. STAT3 is a key regulator of Teff:Treg balance. Using the structure-based design, we have developed a potentially novel small-molecule prodrug LLL12b that specifically inhibits STAT3 and suppresses Th17 differentiation and expansion. Moreover, LLL12b regulates the fate decision between Th17 and Tregs in an inflammatory environment, shifting Th17:Treg balance toward Tregs and favoring the resolution of inflammation. Therapeutic administration of LLL12b after disease onset significantly suppresses disease progression in adoptively transferred, chronic, and relapsing-remitting experimental autoimmune encephalomyelitis. Disease relapses were also significantly suppressed by LLL12b given during the remission phase. Additionally, LLL12b shifts Th17:Treg balance of CD4+ T cells from MS patients toward Tregs and increases Teff sensitivity to Treg-mediated suppression. These data suggest that selective inhibition of STAT3 by the small molecule LLL12b recalibrates the effector and regulatory arms of CD4+ T responses, representing a potentially clinically translatable therapeutic strategy for MS.
65
TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function
Liang Zhou, Jared E. Lopes, Mark M. W. Chong et al. · Nature · 2008 · 1.8K citations
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Ted Yednock, Catherine Cannon, Lawrence C. Fritz et al. · Nature · 1992 · 1.7K citations